STATUS OF PD-1 AND PD-L1 EXPRESSION IN INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER WITH MISMATCH REPAIR PROTEIN DEFICIENCY

被引:0
|
作者
Sungu, Nuran [1 ,2 ,3 ]
Kiran, Merve M. [2 ]
机构
[1] Ankara Yildirim Beyazit Univ, Fac Med, Dept Pathol, Ankara, Turkiye
[2] Ankara City Hosp, Dept Pathol, Ankara, Turkiye
[3] Ankara Yildirim Beyazit Univ, Fac Med, Dept Pathol, Univ Dist 1604 St 9, Cankaya Ankara, Turkiye
关键词
bladder; urothelial cancer; PD-1; PD-L1; MSI; LYNCH SYNDROME; MICROSATELLITE INSTABILITY; IMMUNE ESCAPE; CANCER; CARRIERS; TUMORS; MSH2;
D O I
10.5114/PJP.2023.132221
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
It has been reported that mismatch repair deficient (d-MMR) tumors show sen-sitivity to immune checkpoint inhibitors. We aimed to evaluate the correla-tion of d-MMR and PD-1/PD-L1 expression in invasive urothelial carcinoma of the bladder. Tissue microarray (TMA) tissues were stained PD-1/PD-L1 and MMR proteins. The expression ratio of these markers has been compared with histopathologic parameters. d-MMR tumors were more superficial muscle invasive (p = 0.012). When the d-MMR, and PD-1/PD-L1 expression ratios were examined, a significant correlation was obtained between the d-MMR and PD-L1 expression ratio of > 5% in both the tumor and immune cells (p = 0.02 and p = 0.004, respectively). The expression ratio was higher in the patients without MMR loss. PD-1 and PD-L1expression in those with MSH6 loss was one or none. When PD1/PDL1 expression was compared with histopathological parameters, a significant relationship was observed between tumor grade and depth of muscle invasion. PD-L1 expression was not observed in the superficial muscle invasive tumors. This study was shown the status of d-MMR and PD-1/PD-L1 in invasive urothelial cancers and their correlation with prognostic markers. PD-1/PD-L1 ex -pression may contribute to the progression and poor prognosis of bladder cancer. However, further studies are required to research the clinical utility.
引用
收藏
页码:161 / 170
页数:10
相关论文
共 50 条
  • [21] PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas
    Jenkins, Taylor
    Stoler, Mark
    Cantrell, Leigh
    Mills, Anne
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1073 - 1073
  • [22] Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma
    Tang, Quanqing
    Li, Shihao
    Huang, Gaozhen
    Liu, Hongwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 119
  • [23] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [24] Associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-naive esophageal and gastric adenocarcinoma.
    Svensson, Maria
    Borg, David
    Zhang, Cheng
    Hedner, Charlotta
    Nodin, Bjorn
    Uhlen, Mathias
    Mardinoglu, Adil
    Leandersson, Karin
    Jirstrom, Karin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [25] Urothelial Carcinoma with Sarcomatoid Transformation: An Analysis of PD-L1 Expression Status
    Gupta, Sounak
    Dashti, Nooshin K.
    Thapa, Prabin
    Hernandez, Loren Herrera
    Raghunathan, Aditya
    Sukov, William
    Jimenez, Rafael
    Boorjian, Stephen
    Frank, Igor
    Cheville, John
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 891 - 891
  • [26] Lack of PD-1 and PD-L1 protein expression in pilocytic astrocytoma
    Sinha, Namita
    Phillips, Joanna
    Ersen, Ayca
    Tihan, Tarik
    Gutmann, David
    Dahiya, Sonika
    LABORATORY INVESTIGATION, 2018, 98 : 667 - 667
  • [27] Urothelial Carcinoma with Sarcomatoid Transformation: An Analysis of PD-L1 Expression Status
    Gupta, Sounak
    Dashti, Nooshin K.
    Thapa, Prabin
    Hernandez, Loren Herrera
    Raghunathan, Aditya
    Sukov, William
    Jimenez, Rafael
    Boorjian, Stephen
    Frank, Igor
    Cheville, John
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 891 - 891
  • [28] Lack of PD-1 and PD-L1 protein expression in pilocytic astrocytoma
    Sinha, Namita
    Phillips, Joanna
    Ersen, Ayca
    Tihan, Tarik
    Gutmann, David
    Dahiya, Sonika
    MODERN PATHOLOGY, 2018, 31 : 667 - 667
  • [29] Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
    Shen, Xian
    Zhao, Bin
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [30] Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma
    Krabbe, Laura-Maria
    Heitplatz, Barbara
    Preuss, Sina
    Hutchinson, Ryan C.
    Woldu, Solomon L.
    Singla, Nirmish
    Boegemann, Martin
    Wood, Christopher G.
    Karam, Jose A.
    Weizer, Alon Z.
    Raman, Jay D.
    Remzi, Mesut
    Rioux-Leclercq, Nathalie
    Haitel, Andrea
    Rapoport, Leonid M.
    Glybochko, Peter V.
    Roscigno, Marco
    Bolenz, Christian
    Bensalah, Karim
    Sagalowsky, Arthur I.
    Shariat, Shahrokh F.
    Lotan, Yair
    Xylinas, Evanguelos
    Margulis, Vitaly
    JOURNAL OF UROLOGY, 2017, 198 (06): : 1254 - 1263